Duet BioTherapeutics is focused on developing targeted immunotherapies aimed at treating cancers that are resistant to conventional treatments. Their approach emphasizes the creation of therapies that can specifically engage the immune system to recognize and attack cancer cells, thereby enhancing the body’s natural defenses against tumors. This targeted strategy is particularly crucial for patients who have not responded to existing treatment options, offering new hope for improved outcomes in challenging cases.

The company’s pipeline suggests a commitment to innovative solutions in cancer treatment, leveraging advanced scientific principles to design therapies that are both effective and precise. By concentrating on the unique characteristics of treatment-resistant cancers, Duet BioTherapeutics aims to provide personalized treatment options that can adapt to the evolving nature of cancer, ultimately striving to improve patient survival rates and quality of life.

United States

Duet BioTherapeutics is an immunotherapy company creating a new category of bispecific oligonucleotide treatments designed to target dormant immune cells within the tumor microenvironment. Activation of these antigen-presenting cells removes the immunosuppressive shield around the tumor and jump-starts T cell-mediated immune responses to kill cancer cells.

Duet BioTherapeutics

Company Details